Display options
Cite
Shchelkunov SN, Shchelkunova GA. Genes that Control Vaccinia Virus Immunogenicity. Acta Naturae. 2020;12(1):33-41doi: 10.32607/actanaturae.10935.
Shchelkunov, S. N., & Shchelkunova, G. A. (2020). Genes that Control Vaccinia Virus Immunogenicity. Acta naturae, 12(1), 33-41. https://doi.org/10.32607/actanaturae.10935
Shchelkunov, S N, and Shchelkunova, G A. "Genes that Control Vaccinia Virus Immunogenicity." Acta naturae vol. 12,1 (2020): 33-41. doi: https://doi.org/10.32607/actanaturae.10935
Shchelkunov SN, Shchelkunova GA. Genes that Control Vaccinia Virus Immunogenicity. Acta Naturae. 2020 Jan-Mar;12(1):33-41. doi: 10.32607/actanaturae.10935. PMID: 32477596; PMCID: PMC7245956.
Copy Download .nbib Format: NLM
Share it on

Acta Naturae. 2020 Jan-Mar;12(1):33-41. doi: 10.32607/actanaturae.10935.

Genes that Control Vaccinia Virus Immunogenicity.

Acta naturae

S N Shchelkunov, G A Shchelkunova

Affiliations

  1. State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Novosibirsk region, Koltsovo, 630559 Russia.
  2. The Federal Research Center Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia.
  3. Novosibirsk State University, Novosibirsk, 630090 Russia.

PMID: 32477596 PMCID: PMC7245956 DOI: 10.32607/actanaturae.10935

Abstract

The live smallpox vaccine was a historical first and highly effective vaccine. However, along with high immunogenicity, the vaccinia virus (VACV) caused serious side effects in vaccinees, sometimes with lethal outcomes. Therefore, after global eradication of smallpox, VACV vaccination was stopped. For this reason, most of the human population worldwide lacks specific immunity against not only smallpox, but also other zoonotic orthopoxviruses. Outbreaks of diseases caused by these viruses have increasingly occurred in humans on different continents. However, use of the classical live VACV vaccine for prevention against these diseases is unacceptable because of potential serious side effects, especially in individuals with suppressed immunity or immunodeficiency (e.g., HIV-infected patients). Therefore, highly attenuated VACV variants that preserve their immunogenicity are needed. This review discusses current ideas about the development of a humoral and cellular immune response to orthopoxvirus infection/vaccination and describes genetic engineering approaches that could be utilized to generate safe and highly immunogenic live VACV vaccines.

Copyright ® 2020 National Research University Higher School of Economics.

Keywords: immune modulating proteins; immunogenicity; protectiveness; smallpox; vaccination

References

  1. J Gen Virol. 2013 Jul;94(Pt 7):1647-1657 - PubMed
  2. Virol J. 2006 Mar 01;3:10 - PubMed
  3. Am J Trop Med Hyg. 1972 Mar;21(2):214-8 - PubMed
  4. Viruses. 2018 Feb 28;10(3): - PubMed
  5. Curr Opin Immunol. 2009 Jun;21(3):314-20 - PubMed
  6. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13980-5 - PubMed
  7. Vaccine. 2011 Apr 12;29(17):3276-83 - PubMed
  8. Virology. 2010 Feb 5;397(1):176-86 - PubMed
  9. Vaccine. 2008 Mar 25;26(14):1794-804 - PubMed
  10. J Gen Virol. 2005 Jul;86(Pt 7):1997-2006 - PubMed
  11. Acta Naturae. 2015 Oct-Dec;7(4):113-21 - PubMed
  12. PLoS Pathog. 2015 Sep 03;11(9):e1005151 - PubMed
  13. J Virol. 2007 Aug;81(15):8131-9 - PubMed
  14. Expert Rev Anti Infect Ther. 2019 Feb;17(2):129-139 - PubMed
  15. Nat Biotechnol. 2006 Jul;24(7):817-9 - PubMed
  16. Acta Naturae. 2017 Oct-Dec;9(4):4-12 - PubMed
  17. Virology. 1998 Apr 10;243(2):432-60 - PubMed
  18. Adv Virus Res. 2006;66:31-124 - PubMed
  19. J Gen Virol. 2006 Jan;87(Pt 1):29-38 - PubMed
  20. Proteomics. 2007 May;7(10):1678-86 - PubMed
  21. J Virol. 2006 Jul;80(13):6339-44 - PubMed
  22. Virus Genes. 1995;10(1):53-71 - PubMed
  23. J Virol. 2011 Mar;85(6):2547-56 - PubMed
  24. J Virol. 2012 Dec;86(23):12605-15 - PubMed
  25. PLoS Pathog. 2013;9(12):e1003756 - PubMed
  26. J Gen Virol. 2013 May;94(Pt 5):1121-1126 - PubMed
  27. Subcell Biochem. 2017;83:103-126 - PubMed
  28. Adv Virol. 2012;2012:524743 - PubMed
  29. PLoS One. 2008 Oct 02;3(10):e3323 - PubMed
  30. Dokl Biochem Biophys. 2016;466:35-8 - PubMed
  31. Vaccine. 2017 Dec 19;35(52):7222-7230 - PubMed
  32. Viruses. 2016 May 23;8(5): - PubMed
  33. J Virol. 2008 Apr;82(7):3751-68 - PubMed
  34. J Virol. 2006 Sep;80(18):9244-58 - PubMed
  35. PLoS Pathog. 2015 Sep 01;11(9):e1005148 - PubMed
  36. Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3112-3117 - PubMed
  37. PLoS One. 2012;7(2):e32220 - PubMed
  38. Immunol Rev. 2006 Jun;211:320-37 - PubMed
  39. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63 - PubMed
  40. Virology. 2007 Feb 5;358(1):233-47 - PubMed
  41. Future Microbiol. 2010 Feb;5(2):221-39 - PubMed
  42. J Virol. 2006 Mar;80(5):2127-40 - PubMed
  43. Virology. 2000 Jan 20;266(2):361-86 - PubMed
  44. Vaccine. 2016 Sep 14;34(40):4827-34 - PubMed
  45. Immunol Rev. 2011 Jan;239(1):8-26 - PubMed
  46. Nucleic Acids Res. 2011 Jan;39(Database issue):D576-82 - PubMed
  47. J Immunol. 2019 Mar 1;202(5):1340-1349 - PubMed
  48. Immunology. 2009 Nov;128(3):381-92 - PubMed
  49. Vaccine. 2011 Dec 30;29 Suppl 4:D49-53 - PubMed
  50. J Virol. 2006 Jul;80(13):6333-8 - PubMed

Publication Types